We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 or complete the questionnaire at this link to be contacted about future studies.
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes.
Study Sponsor: F. Hoffmann-La Roche Ltd
Location: International Diabetes Center
Phase of Study: Phase III
Purpose of study: This study is being done to evaluate a new investigational medication for weight management in adults with overweight or obesity. The medication may reduce appetite. The study will see how well the medication works compared to a placebo. A placebo looks like the study drug but has no active ingredient.
What is the cost?
You can participate in this study at no cost. Your participation is completely voluntary.
What happens in the study?
You will be asked to:
– Attend regular study visits for about 18 months
– Have your blood drawn and complete other study procedures
– Take study medicine weekly
– Complete questionnaires using an e-diary
Participants will receive:
– Compensation for completed study visits
– Guidance by nutrition professionals
– Study-related medical care, including regular lab tests, at no cost
Inclusion Criteria:
You may be eligible if you:
– Are 18 years of age or older
– Do not have diabetes
– Have a BMI greater than 27
– Are interested in weight loss
– Are not currently taking weight-loss medication
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)
Study sponsor: Sanofi
Location: International Diabetes Center
Phase of Study: III
Purpose of study: This study is looking at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them. The main goal of the study is to see if teplizumab can work better than a placebo (a look alike with no medicine in it) in helping people keep their blood sugar in a healthy range or use less mealtime insulin. Teplizumab is already FDA approved for use in earlier-stage of type 1 diabetes.
Inclusion Criteria:
To join this study, participants must:
– Be 18 to 25 years of age
– Have been recently diagnosed (within a month) with type 1 diabetes.
– Be positive for at least one T1D autoantibody (proteins that attack insulin-making cells by mistake).
Other criteria may also apply.
Participants will receive all study-related medical care at no cost and will be closely monitored by a doctor throughout the study.
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and type 2 diabetes lose weight
Study Sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: Phase III
Purpose of study: Research Opportunity – Study for new investigational medicine for weight loss and diabetes management
The goal of this study is to evaluate the effect of the investigational medicine called zenagamtide on weight loss in people
with type 2 diabetes
You can participate in this study at no cost. Your participation is completely voluntary.
What happens in the study?
You will be asked to:
– Attend regular study visits for about 2 years
– Undergo blood draws and other study procedures
– Take study medicine weekly during treatment period
– Complete questionnaires using an e-diary
– Complete three periods of continuous glucose monitor (CGM) wear
Participants will receive:
– Compensation for completed study visits
– Guidance by diabetes and nutrition professionals
– Study-related medical care, including regular lab tests, eye exams and EKGs provided at no cost
Inclusion Criteria:
You may be eligible if:
– You are 18 years of age or older
– You have type 2 diabetes
– Have an HbA1c of 7-10%
– You desire weight loss
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
CGM FOR THE EARLY DETECTION AND MANAGEMENT OF HYPERGLYCEMIA IN PREGNANCY (IMAGINE)
Study Sponsor: Leona M. and Harry B. Helmsley Charitable Trust, Dexcom Inc., and Abbott Diabetes
Care, Inc.
Location: International Diabetes Center, Health Center for Women or the Women’s Center
Purpose of study: To better understand how managing glucose levels beginning early in pregnancy may affect the health of the mother and baby. A continuous glucose monitor (CGM) will be used. A continuous glucose monitor or CGM is a device used to track your glucose levels all of the time.
What Happens in the study?
You will be asked to:
– Attend routine prenatal appointments
– Attend 1-2 clinic visits for the study
– Be willing to wear a CGM sensor throughout the entire pregnancy
– Be willing to receive glucose management with CGM or with usual care if you have high blood sugars
Participants will be provided:
– CGM supplies
– Stipend for participation
Inclusion Criteria:
You may be eligible if:
– You are at least 18 years of age
– You are pregnant with one baby
– You will be pregnant for about 14 weeks or less at the first visit with study team
– You speak English or Spanish
– You are receiving your pregnancy care at the Health Center for Women or the Women’s Center
– You do not have diabetes or a history of gestational diabetes
Study Contact:
Shannon Krizka
(952) 993-2092
imaginestudy@healthpartners.com
Medtronic CIP351 GATEWAY
Study Sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: The purpose of this study is to see how well an investigational insulin pump system works to automatically infuse insulin for control of glucose levels for people with type 1 diabetes and type 2 diabetes who use insulin. An insulin pump system can be used instead of injections for some people who use insulin for their diabetes. The system uses continuous glucose readings from the sensor to tell the insulin pump how much insulin to provide to help manage glucose levels in people with type 1 or type 2 diabetes.
– The purpose of this study is to confirm the safety of the investigational insulin pump system with those who
have type 1 or 2 diabetes and use insulin.
– This system consists of the MiniMed NMX8 insulin pump and the DS5 continuous glucose monitor (CGM), and the
Next-Generation iAGC algorithm.
Involvement in the trial will include:
– Use of the insulin pump system including sensors, infusion sets, reservoirs, blood glucose meter and ketone meter,
provided at no cost to you.
– You will be randomly assigned to 1 of 3 groups that will be instructed to use the pump in different ways for
providing insulin with your meals
– Compensation for completed study visits
– Diabetes management and education, support and guidance by the study team
– You will be given the option to continue using the pump system for a period of time after the study has ended.
Inclusion Criteria:
The study is accepting individuals who:
– Are 7-85 years old and have had type 1 diabetes for at least 6 months
OR are 18-85 years old and have had type 2 diabetes for at least 1 year
– Willing to use rapid acting insulin throughout the study. Insulin is not provided to participants. Meet other
qualifying criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP)
Study Sponsor: Abbott Diabetes Care
Location: International Diabetes Center
Purpose of study: Help us better understand glucose patterns for those with or without prediabetes. The purpose of this research study is to observe and identify patterns in how a person’s glucose changes using the FreeStyle Libre 3 Continuous Glucose Monitoring (CGM) System. This study will include people with and without prediabetes. The study includes 2-3 appointments over a period of about 15-20 days. Information collected in this study could lead to new and potentially more effective methods to diagnose prediabetes and may help to better understand ways in which continuous glucose monitoring can be used for persons with prediabetes or glucose tolerance issues.
Participants will receive:
– The study system to use during participation
– Compensation for completed visits
– Study related lab tests at no cost
Inclusion Criteria:
You may qualify if you:
– Have been diagnosed with prediabetes. The study is also enrolling those who do not have prediabetes.
– Are not taking medications for diabetes or weight loss
– Are willing to wear a continuous glucose monitor
– Are willing to complete an oral glucose tolerance test
– Meet other study specific requirements
Exclusion Criteria:
– Individuals with a diagnosis of diabetes are not eligible.
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes
Study Sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: Phase III
Purpose of study:
We are conducting a research study for people with type 1 diabetes comparing a once weekly basal insulin to once daily basal insulin.
We will provide participants one of two different long-acting insulins at no cost, to see how much it helps with managing blood sugars. We are also providing mealtime insulin at no cost. We are doing this study to look at how much a new investigational once weekly insulin improves blood sugar in people with type 1 diabetes. This will be compared to a currently available once daily basal insulin.
Participants will receive a stipend for completed visits.
Dexcom G7 continuous glucose monitoring (CGM) supplies will be provided at no cost.
Inclusion Criteria:
We are inviting all adults who:
– Have type 1 diabetes
– Take multiple injections of insulin a day
– Have an A1C 7-10%.
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
